XNASBYSI
Market cap65mUSD
Jan 08, Last price
1.63USD
1D
-5.23%
1Q
-31.44%
IPO
-91.53%
Name
Beyondspring Inc
Chart & Performance
P/E
—
P/S
37.52
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
11.46%
Rev. gr., 5y
0.00%
Revenues
2m
+29.61%
Net income
-21m
L-42.05%
CFO
-16m
L-40.02%
Profile
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
IPO date
Mar 09, 2017
Employees
73
Domiciled in
US
Incorporated in
KY
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 1,751 29.61% | 1,351 0.00% | |||||||
Cost of revenue | 24,865 | 38,590 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (23,114) | (37,239) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 106 | 163 | |||||||
Tax Rate | |||||||||
NOPAT | (23,220) | (37,402) | |||||||
Net income | (21,026) -42.05% | (36,280) -46.81% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 631 | 966 | |||||||
Long-term debt | 7,359 | 8,956 | |||||||
Deferred revenue | 33,242 | 34,221 | |||||||
Other long-term liabilities | 3,705 | 3,661 | |||||||
Net debt | (12) | (27,346) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (16,474) | (27,464) | |||||||
CAPEX | (100) | (34) | |||||||
Cash from investing activities | (100) | 17,560 | |||||||
Cash from financing activities | 4 | 3,431 | |||||||
FCF | (24,999) | (39,804) | |||||||
| Balance | |||||||||
Cash | 8,002 | 37,268 | |||||||
Long term investments | |||||||||
Excess cash | 7,914 | 37,200 | |||||||
Stockholders' equity | (392,060) | (371,864) | |||||||
Invested Capital | 409,541 | 411,668 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 38,996 | 39,093 | |||||||
Price | 0.90 -52.13% | 1.88 -58.50% | |||||||
Market cap | 35,097 -52.25% | 73,495 -58.42% | |||||||
EV | 38,429 | 49,121 | |||||||
EBITDA | (22,812) | (37,007) | |||||||
EV/EBITDA | |||||||||
Interest | 17 | ||||||||
Interest/NOPBT | |||||||||